Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Seres Therapeutics (MCRB) Tops Q3 EPS by 9c, Revenues Beat
November 5, 2019 7:39 AM ESTSeres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $7.03 million versus the consensus estimate of $6.7 million.
Seres continues to advance our microbiome programs, and the Company is well resourced to reach important corporate... More
